Wall Street equity research analysts covering Arcturus Therapeutics publish twelve-month consensus price targets that generally hover around $20 to $21 per share. These forward-looking projections vary widely among individual financial institutions depending on anticipated clinical trial milestones, regulatory approvals for pipeline assets, and broader market sentiment toward small-cap biotech equities.